PHAT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PHAT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Phathom Pharmaceuticals's interest income for the three months ended in Sep. 2024 was $3.71 Mil. Its interest income for the trailing twelve months (TTM) ended in Sep. 2024 was $15.00 Mil.
The historical data trend for Phathom Pharmaceuticals's Interest Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phathom Pharmaceuticals Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Interest Income | Get a 7-Day Free Trial | 1.09 | 1.09 | 0.04 | 2.13 | 7.88 |
Phathom Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Interest Income | Get a 7-Day Free Trial | 2.72 | 3.35 | 4.31 | 3.62 | 3.71 |
Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.
Interest Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Azmi Nabulsi | officer: Chief Operating Officer | C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089 |
Terrie Curran | director | C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018 |
Molly Henderson | officer: CFO and CBO | 305 COLLEGE ROAD EAST, PRINCETON NJ 08540 |
Takeda Pharmaceutical Co Ltd | 10 percent owner | 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668 |
Asit Parikh | director | C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089 |
Frank Karbe | director | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
David A Socks | director, officer: President, CEO, Treas. & Sec. | C/O CADENCE PHARMACEUTICALS, INC., 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Anthony J. Guzzo | officer: VP, Chief Accounting Officer | C/O US SHIPPING PARTNERS L.P., 399 THORNALL STREET, EDISON NJ 08837 |
Ra Capital Healthcare Fund Lp | 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Todd P. Branning | officer: Chief Financial Officer | C/O AMNEAL PHARMACEUTICLAS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807 |
Mark Stenhouse | director | 5505 ENDEAVOR LANE, MADISON WI 53719 |
Michael F Cola | director | 435 DEVON PARK BUILDING 800, WAYNE PA 19087-1945 |
Frazier Life Sciences Ix, L.p. | 10 percent owner | 601 UNION STREET, SUITE 3200, SEATTLE WA 98101 |
Jonathan S. Edwards | director | C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089 |
Rajeev M. Shah | 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
From GuruFocus
By Marketwired • 07-29-2024
By Marketwired • 11-07-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By Marketwired • 05-09-2024
By GlobeNewswire • 10-27-2024
By GuruFocus News • 11-08-2024
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 03-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.